Claims for Patent: 6,358,709

Summary for Patent: 6,358,709

Title:	End selection in directed evolution
Abstract:	This invention provides methods of obtaining novel polynucleotides and encoded polypeptides by the use of non-stochastic methods of directed evolution (DirectEvolution.TM.). A particular advantage of end-selection-based methods is the ability to recover full-length polynucleotides from a library of progeny molecules generated by mutagenesis methods. These methods include non-stochastic polynucleotide site-saturation mutagenesis (Gene Site Saturation Mutagenesis.TM.) and non-stochastic polynucleotide reassembly (GeneReassembly.TM.). This invention provides methods of obtaining novel enzymes that have optimized physical &/or biological properties. Through use of the claimed methods, genetic vaccines, enzymes, small molecules, and other desirable molecules can be evolved towards desirable properties. For example, vaccine vectors can be obtained that exhibit increased efficacy for use as genetic vaccines. Vectors obtained by using the methods can have, for example, enhanced antigen expression, increased uptake into a cell, increased stability in a cell, ability to tailor an immune response, and the like. Furthermore, this invention provides methods of obtaining a variety of novel biologically active molecules, in the fields of antibiotics, pharmacotherapeutics, and transgenic traits.
Inventor(s):	Short; Jay M. (Encinitas, CA), Frey; Gerhard Johann (San Diego, CA)
Assignee:	Diversa Corporation (San Diego, CA)
Application Number:	09/522,289
Patent Claims:	1. A method for producing a polynucleotide encoding a polypeptide having at least one desirable property, the method comprising: (a) subjecting a plurality of first polynucleotides to simultaneous mutagenesis so as to produce a plurality of progeny polynucleotides; said mutagenesis comprising subjecting a codon-containing template polynucleotide to polymerase-based amplification using a plurality of degenerate oligonucleotides for each codon to be mutagenized, where each of said degenerate oligonucleotides contains a degenerate triplet sequence, so as to generate a plurality of progeny polynucleotides; and (b) subjecting the plurality of progeny polynucleotides to end-selection screening to select progeny polynucleotides encoding a polypeptide having at least one desirable property. 2. The method according to claim 1 wherein a 32-fold degenerate oligonucleotide is used for each codon to be mutagenized. 3. A method according to claim 2, wherein said 32-fold degenerate oligonucleotide comprises a plurality of degenerate triplet sequences. 4. The method according to claim 3 wherein the degeneracy of the triplet sequence includes multiple codons for all 20 amino acids. 5. The method according to claim 2 wherein each nucleotide position in the degenerate triplet sequence is N, A, C, G, T, A/C, A/G, A/T, C/G, C/T, G/T, C/G/T, A/G/T, A/C/T, A/C/G, or E, where E is any base that is not A, C, G or T and wherein N is any nucleotide base or a derivative thereof. 6. The method according to claim 1 wherein the degenerate triplet sequence is N,N,G/T, N,N,C/G, N,N,N or N,N,A/C wherein N is any nucleotide base or a derivative thereof. 7. The method according to claim 2 wherein the degeneracy of the triplet sequence includes codons for all 20 amino acids such that all 20 amino acid changes are generated at each amino acid site along a parental polypeptide template encoded by the plurality of first polynucleotides. 8. The method according to claim 1 wherein the progeny polynucleotides are subjected to an end selection based screening that creates ligation-compatible ends. 9. The method according to claim 8 wherein ligation-compatible ends cause intermolecular ligations among members of the plurality of progeny polynucleotides. 10. The method according to claim 9 wherein the intermolecular ligations are directional. 11. The method according to claim 1 further comprising (c) screening a plurality of progeny polypeptides encoded by the progeny polynucleotides to select one or more thereof that have a desirable property. 12. The method according to claim 11 wherein the screening of the plurality of progeny polypeptides comprises clonal amplification in a host cell. 13. The method according to claim 11 wherein steps (a) and (b) are repeated prior to performing step (c). 14. The method according to claim 1 wherein the method is performed iteratively. 15. The method according to claim 1 wherein the plurality of first polynucleotides encode a parental polypeptide template and the plurality of progeny polynucleotides have codon substitutions corresponding to a full range of single amino acid substitutions at each amino acid position in the parental polypeptide. 16. The method according to claim 1 wherein the amplification is incomplete so that fragments of the parental polynucleotide template are thereby created. 17. The method according to claim 1 wherein the desirable property is a specific enzymatic activity. 18. The method according to claim 1 further comprising generating a plurality of fragments of the plurality of first polynucleotides to obtain a plurality of codon-containing polynucleotide fragments prior to the mutagenesis process. 19. The method according to claim 1 wherein the plurality of first polynucleotides correspond to a template polynucleotide that contains from 15 to about 100,000 bases to be mutagenized. 20. The method according to claim 1 wherein the mutagenesis employs a mutagenic primer containing a mutagenic cassette. 21. The method according to claim 20 wherein the mutagenic cassette has from 1 to about 500 bases and wherein a group of mutations ranging from 1 to 100 is introduced into each cassette. 22. The method according to claim 21 wherein the group of mutations introduced into a first cassette is different from a group of mutations introduced into a second cassette during a single round of saturation mutagenesis. 23. The method according to claim 21 wherein each base in the cassette is N, A, C, G, T, A/C, A/G, A/T, C/G, C/T, C/G/T, A/G/T, A/C/T, A/C/G or E, wherein E is any base that is not A, C, G or T, and wherein N is any nucleotide base or a derivative thereof. 24. The method according to claim 1 wherein only one portion of the first polynucleotides is subjected to the mutagenesis. 25. The method according to claim 24 wherein the portion corresponds to a whole gene, a gene pathway, a cDNA, an entire open reading frame, a complete promoter, an enhancer, a repressor/transactivator, an origin of replication, an intron, an operator, or any other polynucleotide functional group. 26. The method according to claim 24 wherein the portion is a base sequence of from 15 to about 15,000 bases. 27. The method according to claim 1 wherein the degenerate oligonucleotides encode from 2 to 20 amino acids at each codon position. 28. The method according to claim 1 further comprising sequencing a progeny polypeptide that is selected as having a desirable property to determine a first mutation that contributes to the desirable property. 29. The method according to claim 28 wherein the method is repeated to determine a second mutation that contributes to the desirable property. 30. The method according to claim 1 wherein a separate nucleotide is used for mutagenizing each position or group of positions along each of the plurality of first polynucleotides. 31. The method according to claim 1 wherein the screening utilizes a high throughput screening technique. 32. A method for producing a mutant molecule having at least one desirable property, the method comprising: (a) subjecting a plurality of first polynucleotides to simultaneous mutagenesis so as to produce a plurality of progeny polynucleotides, wherein the mutagenesis comprises subjecting a codon-containing template polynucleotide to amplification using a plurality of degenerate oligonucleotide for each codon to be mutagenized, wherein the degenerate oligonucleotides each comprise a first homologous sequence and a plurality of degenerate triplet sequences, and (b) subjecting the progeny polynucleotides to an end selection-based screening and enrichment process that creates ligation-compatible ends, so as to select one or more progeny polynucleotides encoding at least one desirable property. 33. The method according to claim 32 wherein the degeneracy of the triplet sequences includes multiple codons for all 20 amino acids. 34. The method according to claim 33 wherein each nucleotide position in the degenerate triplet sequences is N, A, C, G, T, A/C, A/G, A/T, C/G, C/T, G/T, C/G/T, A/G/T, A/C/T, A/C/G, or E, where E is any base that is not A, C, G or T and wherein N is any nucleotide base or a derivative thereof. 35. The method according to claim 33 wherein each degenerate triplet sequences is N,N,C/G/T, N,N,C/T, N,N,N or N,N,A/C, wherein N is any nucleotide base or a derivative thereof. 36. The method according to claim 32 wherein the degeneracy of the oligonucleotide includes codons for all 20 amino acids such that all 20 amino acid changes are generated at each amino acid site along a parental polypeptide template encoded by the plurality of first polynucleotides.

Details for Patent 6,358,709

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2015-12-07
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2015-12-07
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2015-12-07